-
Visen Pharmaceuticals IPO Launches on Hong Kong Stock Exchange Amid Growth in Endocrine Therapies
•
China-based Visen Pharmaceuticals, a joint venture between Denmark-headquartered Ascendis Pharma and Vivo Capital, has successfully launched its initial public offering (IPO) on the Hong Kong Stock Exchange. The offering price ranges from HKD68.44 to HKD75.28 per share, with net proceeds potentially reaching HKD603.3 million (USD77.6 million) if calculated at the…
-
Anhui Anke to Invest in Visen Pharma’s Hong Kong IPO as Cornerstone Investor
•
China – based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced its plan to subscribe to shares of Visen Pharmaceuticals via its initial public offering (IPO) on the Hong Kong Stock Exchange. Anhui Anke will invest up to USD31 million as a cornerstone investor. About Visen PharmaceuticalsVisen Pharmaceuticals…
-
Ascendis Pharma’s Hypoparathyroidism Therapy Yorvipath Wins FDA Nod, Fills Market Gap
•
This week, the U.S. Food and Drug Administration (FDA) granted market approval to Ascendis Pharma A/S (NASDAQ: ASND), a Denmark-based pharmaceutical company specializing in rare diseases, for its hypoparathyroidism treatment, palopegteriparatide. The therapy, to be marketed as Yorvipath, is a once-daily prodrug of parathyroid hormone (PTH[1-34]) designed to address the…
-
Visen Pharmaceuticals’ TransCon hGH Accepted for Review by China’s NMPA
•
Visen Pharmaceuticals, a joint venture between Denmark-based Ascendis Pharma and Chinese healthcare-focused investment firm Vivo Capital, has announced that the National Medical Products Administration (NMPA) has accepted for review a marketing approval filing for its lonapegsomatropin, TransCon hGH, a once-weekly long-acting growth hormone. This drug, which is the first long-acting…
-
Visen Pharmaceuticals Reports Positive Phase II Results for TransCon CNP in Achondroplasia
•
Visen Pharmaceuticals, a joint venture between Denmark-based Ascendis Pharma A/S (NASDAQ: ASND) and Chinese healthcare investment firm Vivo Capital, has announced topline results from the ACcomplisH China Phase II trial. The study assessed the safety and efficacy of once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACH) aged 2 to…
-
Visen Pharmaceuticals Files for Hong Kong IPO with Focus on Growth Hormone
•
Visen Pharmaceuticals, a China-based joint venture between Denmark-headquartered Ascendis Pharma and Chinese healthcare-focused investment firm Vivo Capital, has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange. Morgan Stanley and Jefferies are acting as co-sponsors. The proceeds will be used to support research and development (R&D)…
-
Visen Pharmaceuticals Publishes Phase III Data for Lonapegsomatropin in Growth Hormone Deficiency
•
Visen Pharmaceuticals, a China-based joint venture between Denmark-headquartered Ascendis Pharma and Chinese healthcare-focused investment firm Vivo Capital, has published primary data from a pivotal Phase III study for its lonapegsomatropin, also known as TransCon hGH, a once-weekly long-acting growth hormone. The study evaluated the efficacy and safety of lonapegsomatropin in…
